Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver

被引:1
作者
Kuriyama, S [1 ]
Tominaga, K [1 ]
Kikukawa, M [1 ]
Nakatani, T [1 ]
Tsujinoue, H [1 ]
Yamazaki, M [1 ]
Nagao, S [1 ]
Toyokawa, Y [1 ]
Mitoro, A [1 ]
Fukui, H [1 ]
机构
[1] Nara Med Univ, Dept Internal Med 3, Kashihara, Nara 6348522, Japan
关键词
gene therapy; adenovirus; anti-adenovirus antibody; neutralizing antibody; human serum; gene transfer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent advances in molecular biology have made gene therapy for cancer feasible in clinical trials Although recombinant adenovirus is an attractive vehicle for transferring therapeutic genes in vivo, animal studies have indicated that the clinical usefulness of adenovirus vectors may be limited by their immunogenicity. It has been shown that neutralizing antibodies against adenoviruses reduce the efficiency of vector readministration. It is of great importance to examine the effects of human sera on adenovirus-mediated gene transfer, because the majority of prospective gene therapy patients are likely to have been exposed to wild-type adenoviruses. In the present study it was shown that anti-adenovirus antibody-positive human sera with the lowest positive titer substantially inhibit the adenovirus-mediated gene transfer not only in vitro but also in vivo. These results may have important implications for efficacy considerations when adenovirus vectors are employed in the clinical setting.
引用
收藏
页码:2345 / 2351
页数:7
相关论文
共 40 条
[1]   Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial [J].
Bellon, G ;
MichelCalemard, L ;
Thouvenot, D ;
Jagneaux, V ;
Poitevin, F ;
Malcus, C ;
Accart, N ;
Layani, MP ;
Aymard, M ;
Bernon, H ;
Bienvenu, J ;
Courtney, M ;
Doring, G ;
Gilly, B ;
Gilly, R ;
Lamy, D ;
Levrey, H ;
Morel, Y ;
Paulin, C ;
Perraud, F ;
Rodillon, L ;
Sene, C ;
So, S ;
TouraineMoulin, F ;
Schatz, C ;
Pavirani, A .
HUMAN GENE THERAPY, 1997, 8 (01) :15-25
[2]  
Byrnes AP, 1996, GENE THER, V3, P644
[3]   ADMINISTRATION OF AN ADENOVIRUS CONTAINING THE HUMAN CFTR CDNA TO THE RESPIRATORY-TRACT OF INDIVIDUALS WITH CYSTIC-FIBROSIS [J].
CRYSTAL, RG ;
MCELVANEY, NG ;
ROSENFELD, MA ;
CHU, CS ;
MASTRANGELI, A ;
HAY, JG ;
BRODY, SL ;
JAFFE, HA ;
EISSA, NT ;
DANEL, C .
NATURE GENETICS, 1994, 8 (01) :42-51
[4]   CELLULAR AND HUMORAL IMMUNE-RESPONSES TO ADENOVIRAL VECTORS CONTAINING FACTOR-IX GENE - TOLERIZATION OF FACTOR-IX AND VECTOR ANTIGENS ALLOWS FOR LONG-TERM EXPRESSION [J].
DAI, YF ;
SCHWARZ, EM ;
GU, DL ;
ZHANG, WW ;
SARVETNICK, N ;
VERMA, IM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1401-1405
[5]   Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector [J].
Dong, JY ;
Wang, DH ;
VanGinkel, FW ;
Pascual, DW ;
Frizzell, RA .
HUMAN GENE THERAPY, 1996, 7 (03) :319-331
[6]   ABLATION OF E2A IN RECOMBINANT ADENOVIRUSES IMPROVES TRANSGENE PERSISTENCE AND DECREASES INFLAMMATORY RESPONSE IN MOUSE-LIVER [J].
ENGELHARDT, JF ;
YE, XH ;
DORANZ, B ;
WILSON, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :6196-6200
[7]  
Fang B, 1996, GENE THER, V3, P217
[8]   TRANSFER OF THE CFTR GENE TO THE LUNG OF NONHUMAN-PRIMATES WITH E1-DELETED, E2A-DEFECTIVE RECOMBINANT ADENOVIRUSES - A PRECLINICAL TOXICOLOGY STUDY [J].
GOLDMAN, MJ ;
LITZKY, LA ;
ENGELHARDT, JF ;
WILSON, JM .
HUMAN GENE THERAPY, 1995, 6 (07) :839-851
[9]  
Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109
[10]   CHARACTERISTICS OF A HUMAN CELL LINE TRANSFORMED BY DNA FROM HUMAN ADENOVIRUS TYPE-5 [J].
GRAHAM, FL ;
SMILEY, J ;
RUSSELL, WC ;
NAIRN, R .
JOURNAL OF GENERAL VIROLOGY, 1977, 36 (JUL) :59-72